Apperley JF - Search Results

1

Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies.

Cook LB, O'Dell G, Vourvou E, Palanicawandar R, Marks S, Milojkovic D, Apperley JF, Loaiza S, Claudiani S, Bua M, Hockings C, Macdonald D, Chaidos A, Pavlu J, Cooper N, Fidler S, Randell P, Innes AJ. Cook LB, et al. Among authors: apperley jf. Nat Commun. 2022 Nov 14;13(1):6922. doi: 10.1038/s41467-022-34657-z. Nat Commun. 2022. PMID: 36376307 Free PMC article.

2

Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia.

Wadhwa J, Szydlo RM, Apperley JF, Chase A, Bua M, Marin D, Olavarria E, Kanfer E, Goldman JM. Wadhwa J, et al. Among authors: apperley jf. Blood. 2002 Apr 1;99(7):2304-9. doi: 10.1182/blood.v99.7.2304. Blood. 2002. PMID: 11895760 Free article.

3

Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.

Marktel S, Marin D, Foot N, Szydlo R, Bua M, Karadimitris A, De Melo VA, Kotzampaltiris P, Dazzi F, Rahemtulla A, Olavarria E, Apperley JF, Goldman JM. Marktel S, et al. Among authors: apperley jf. Haematologica. 2003 Mar;88(3):260-7. Haematologica. 2003. PMID: 12651263 Clinical Trial.

4

Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa.

Marin D, Marktel S, Szydlo R, Klein JP, Bua M, Foot N, Olavarria E, Shepherd P, Kanfer E, Goldman JM, Apperley JF. Marin D, et al. Among authors: apperley jf. Lancet. 2003 Aug 23;362(9384):617-9. doi: 10.1016/S0140-6736(03)14182-7. Lancet. 2003. PMID: 12944062 Clinical Trial.

5

Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.

Marin D, Kaeda JS, Andreasson C, Saunders SM, Bua M, Olavarria E, Goldman JM, Apperley JF. Marin D, et al. Among authors: apperley jf. Cancer. 2005 May 1;103(9):1850-5. doi: 10.1002/cncr.20975. Cancer. 2005. PMID: 15786422 Free article. Clinical Trial.

6

LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.

Perz JB, Giles C, Szydlo R, O'Shea D, Sanz J, Chaidos A, Wagner S, Davis J, Loaiza S, Marin D, Apperley J, Olavarria E, Rahemtulla A, Lampert I, Naresh K, Samson D, MacDonald D, Kanfer EJ. Perz JB, et al. Bone Marrow Transplant. 2007 Jan;39(1):41-7. doi: 10.1038/sj.bmt.1705544. Epub 2006 Nov 20. Bone Marrow Transplant. 2007. PMID: 17115062

7

Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission.

Pavlu J, Andreasson C, Chuah C, Kaeda J, Goldman JM, Apperley JF, Marin D. Pavlu J, et al. Among authors: apperley jf. Br J Haematol. 2007 Jun;137(5):423-8. doi: 10.1111/j.1365-2141.2007.06578.x. Epub 2007 Apr 11. Br J Haematol. 2007. PMID: 17428238 Free article. Clinical Trial.

8

Impact of HLA class I and class II DNA high-resolution HLA typing on clinical outcome in adult unrelated stem cell transplantation after in vivo T-cell depletion with alemtuzumab.

Perz JB, Szydlo R, Sergeant R, Sanz J, O'Shea D, Khan T, Davey N, Loaiza S, Davis J, Apperley JF, Olavarria E. Perz JB, et al. Among authors: apperley jf. Transpl Immunol. 2007 Nov;18(2):179-85. doi: 10.1016/j.trim.2007.05.002. Epub 2007 Jun 15. Transpl Immunol. 2007. PMID: 18005865

9

State-of-the-art in the treatment of chronic myeloid leukaemia.

Milojkovic D, Apperley J. Milojkovic D, et al. Curr Opin Oncol. 2008 Jan;20(1):112-21. doi: 10.1097/CCO.0b013e3282f1fe8a. Curr Opin Oncol. 2008. PMID: 18043265 Review.

10

Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements.

De Melo VA, Milojkovic D, Marin D, Apperley JF, Nacheva EP, Reid AG. De Melo VA, et al. Among authors: apperley jf. Cancer Genet Cytogenet. 2008 Apr 15;182(2):111-5. doi: 10.1016/j.cancergencyto.2008.01.007. Cancer Genet Cytogenet. 2008. PMID: 18406872

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

347 results

Search Page